AP
VRTX icon

Appleton Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Appleton Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$849K Sell
1,710
-79
-4% -$35K 0.05% 163
2026
Q1 		$799K Sell
1,789
-19
-1% -$8.86K 0.06% 153
2025
Q4 		$820K Hold
1,808
– – 0.05% 154
2025
Q3 		$708K Hold
1,808
– – 0.05% 159
2025
Q2 		$805K Buy
1,808
+15
+0.8% +$6.91K 0.06% 147
2025
Q1 		$869K Sell
1,793
-15
-0.8% -$6.99K 0.07% 135
2024
Q4 		$728K Buy
1,808
+4
+0.2% +$1.85K 0.05% 147
2024
Q3 		$839K Hold
1,804
– – 0.06% 141
2024
Q2 		$846K Sell
1,804
-42
-2% -$18.2K 0.07% 141
2024
Q1 		$772K Sell
1,846
-219
-11% -$92.6K 0.06% 151
2023
Q4 		$840K Sell
2,065
-1,196
-37% -$442K 0.07% 148
2023
Q3 		$1.13M Sell
3,261
-349
-10% -$122K 0.1% 126
2023
Q2 		$1.27M Sell
3,610
-186
-5% -$62.7K 0.11% 131
2023
Q1 		$1.2M Sell
3,796
-1,287
-25% -$386K 0.11% 140
2022
Q4 		$1.47M Sell
5,083
-477
-9% -$145K 0.14% 130
2022
Q3 		$1.61M Sell
5,560
-242
-4% -$69.6K 0.16% 121
2022
Q2 		$1.64M Sell
5,802
-405
-7% -$108K 0.15% 121
2022
Q1 		$1.62M Sell
6,207
-925
-13% -$220K 0.13% 133
2021
Q4 		$1.57M Sell
7,132
-1,500
-17% -$292K 0.12% 139
2021
Q3 		$1.57M Sell
8,632
-825
-9% -$161K 0.13% 133
2021
Q2 		$1.91M Sell
9,457
-1,120
-11% -$234K 0.16% 120
2021
Q1 		$2.27M Sell
10,577
-451
-4% -$99.1K 0.21% 107
2020
Q4 		$2.61M Buy
11,028
+291
+3% +$66.8K 0.26% 86
2020
Q3 		$2.92M Buy
10,737
+822
+8% +$227K 0.32% 77
2020
Q2 		$2.88M Buy
9,915
+628
+7% +$170K 0.34% 77
2020
Q1 		$2.21M Sell
9,287
-55
-0.6% -$12.6K 0.31% 81
2019
Q4 		$2.04M Buy
9,342
+807
+9% +$163K 0.22% 107
2019
Q3 		$1.45M Buy
+8,535
New +$1.51M 0.17% 121

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Appleton Partners's VRTX Position: Q2 2026 in Review

Appleton Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 4.4% in Q2 2026, selling an estimated $35K and leaving 1,710 shares worth $849K. The position accounts for 0.05% of the portfolio, ranked #163.

Appleton Partners first reported a position in VRTX in Q3 2019 and has held it in 28 quarters since. The position peaked at $2.92M in Q3 2020. 334 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Appleton Partners held 1,710 shares of Vertex Pharmaceuticals worth $849K as of Q2 2026.
  • Appleton Partners sold 79 Vertex Pharmaceuticals shares in Q2 2026, an estimated $35K.
  • Vertex Pharmaceuticals made up 0.05% of Appleton Partners's portfolio in Q2 2026, its #163 holding.
  • Appleton Partners first reported a position in Vertex Pharmaceuticals in Q3 2019 and has held it in 28 quarters since.
  • Appleton Partners's Vertex Pharmaceuticals position peaked at $2.92M in Q3 2020.
  • 334 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Appleton Partners's 13F filing for Q2 2026, filed 21 Jul 2026.